These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
373 related articles for article (PubMed ID: 39252946)
21. Advances in Bone-targeted Drug Delivery Systems for Neoadjuvant Chemotherapy for Osteosarcoma. Li CJ; Liu XZ; Zhang L; Chen LB; Shi X; Wu SJ; Zhao JN Orthop Surg; 2016 May; 8(2):105-10. PubMed ID: 27384718 [TBL] [Abstract][Full Text] [Related]
22. Osteosarcoma and Metastasis. Sheng G; Gao Y; Yang Y; Wu H Front Oncol; 2021; 11():780264. PubMed ID: 34956899 [TBL] [Abstract][Full Text] [Related]
23. Effects of microenvironment in osteosarcoma on chemoresistance and the promise of immunotherapy as an osteosarcoma therapeutic modality. Yu L; Zhang J; Li Y Front Immunol; 2022; 13():871076. PubMed ID: 36311748 [TBL] [Abstract][Full Text] [Related]
24. Broad targeting of angiogenesis for cancer prevention and therapy. Wang Z; Dabrosin C; Yin X; Fuster MM; Arreola A; Rathmell WK; Generali D; Nagaraju GP; El-Rayes B; Ribatti D; Chen YC; Honoki K; Fujii H; Georgakilas AG; Nowsheen S; Amedei A; Niccolai E; Amin A; Ashraf SS; Helferich B; Yang X; Guha G; Bhakta D; Ciriolo MR; Aquilano K; Chen S; Halicka D; Mohammed SI; Azmi AS; Bilsland A; Keith WN; Jensen LD Semin Cancer Biol; 2015 Dec; 35 Suppl(Suppl):S224-S243. PubMed ID: 25600295 [TBL] [Abstract][Full Text] [Related]
25. Advanced development of ErbB family-targeted therapies in osteosarcoma treatment. Wang W; Zhao HF; Yao TF; Gong H Invest New Drugs; 2019 Feb; 37(1):175-183. PubMed ID: 30353245 [TBL] [Abstract][Full Text] [Related]
26. Translational nanomedicine potentiates immunotherapy in sarcoma by normalizing the microenvironment. Mpekris F; Panagi M; Michael C; Voutouri C; Tsuchiya M; Wagatsuma C; Kinoh H; Osada A; Akinaga S; Yoshida S; Martin JD; Stylianopoulos T J Control Release; 2023 Jan; 353():956-964. PubMed ID: 36516902 [TBL] [Abstract][Full Text] [Related]
27. Current Status and Prospects of Targeted Therapy for Osteosarcoma. Hu Z; Wen S; Huo Z; Wang Q; Zhao J; Wang Z; Chen Y; Zhang L; Zhou F; Guo Z; Liu H; Zhou S Cells; 2022 Nov; 11(21):. PubMed ID: 36359903 [TBL] [Abstract][Full Text] [Related]
28. Targeted therapy for osteosarcoma: a review. Li S; Zhang H; Liu J; Shang G J Cancer Res Clin Oncol; 2023 Aug; 149(9):6785-6797. PubMed ID: 36807762 [TBL] [Abstract][Full Text] [Related]
29. The application and research progress of anti-angiogenesis therapy in tumor immunotherapy. Tu J; Liang H; Li C; Huang Y; Wang Z; Chen X; Yuan X Front Immunol; 2023; 14():1198972. PubMed ID: 37334350 [TBL] [Abstract][Full Text] [Related]
30. Current Status and Prospects of Clinical Treatment of Osteosarcoma. Jiang ZY; Liu JB; Wang XF; Ma YS; Fu D Technol Cancer Res Treat; 2022; 21():15330338221124696. PubMed ID: 36128851 [TBL] [Abstract][Full Text] [Related]
31. The molecular pathogenesis of osteosarcoma: a review. Broadhead ML; Clark JC; Myers DE; Dass CR; Choong PF Sarcoma; 2011; 2011():959248. PubMed ID: 21559216 [TBL] [Abstract][Full Text] [Related]
32. CAR T targets and microenvironmental barriers of osteosarcoma. Zhu J; Simayi N; Wan R; Huang W Cytotherapy; 2022 Jun; 24(6):567-576. PubMed ID: 35193828 [TBL] [Abstract][Full Text] [Related]
33. Curcumin in Osteosarcoma Therapy: Combining With Immunotherapy, Chemotherapeutics, Bone Tissue Engineering Materials and Potential Synergism With Photodynamic Therapy. Xu C; Wang M; Guo W; Sun W; Liu Y Front Oncol; 2021; 11():672490. PubMed ID: 34094974 [TBL] [Abstract][Full Text] [Related]
34. Anti-angiogenic therapy for osteosarcoma. Quan GM; Choong PF Cancer Metastasis Rev; 2006 Dec; 25(4):707-13. PubMed ID: 17160710 [TBL] [Abstract][Full Text] [Related]
35. Melatonin: an anti-tumor agent for osteosarcoma. Fathizadeh H; Mirzaei H; Asemi Z Cancer Cell Int; 2019; 19():319. PubMed ID: 31798348 [TBL] [Abstract][Full Text] [Related]
36. Can cure in patients with osteosarcoma be achieved exclusively with chemotherapy and abrogation of surgery? Jaffe N; Carrasco H; Raymond K; Ayala A; Eftekhari F Cancer; 2002 Nov; 95(10):2202-10. PubMed ID: 12412175 [TBL] [Abstract][Full Text] [Related]
37. Non-randomized therapy trial to determine the safety and efficacy of heavy ion radiotherapy in patients with non-resectable osteosarcoma. Blattmann C; Oertel S; Schulz-Ertner D; Rieken S; Haufe S; Ewerbeck V; Unterberg A; Karapanagiotou-Schenkel I; Combs SE; Nikoghosyan A; Bischof M; Jäkel O; Huber P; Kulozik AE; Debus J BMC Cancer; 2010 Mar; 10():96. PubMed ID: 20226028 [TBL] [Abstract][Full Text] [Related]
38. Future directions in the treatment of osteosarcoma. Bishop MW; Janeway KA; Gorlick R Curr Opin Pediatr; 2016 Feb; 28(1):26-33. PubMed ID: 26626558 [TBL] [Abstract][Full Text] [Related]
39. [Progress of osteosarcoma therapy]. Qiu Z; Liao Q Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2010 Dec; 24(12):1469-75. PubMed ID: 21261096 [TBL] [Abstract][Full Text] [Related]
40. New Insights about the Wnt/β-Catenin Signaling Pathway in Primary Bone Tumors and Their Microenvironment: A Promising Target to Develop Therapeutic Strategies? Danieau G; Morice S; Rédini F; Verrecchia F; Royer BB Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31370265 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]